Gestational Trophoblastic Disease: Prevalence, Management and Follow-Up at a Tertiary Center in Oman—An 11-Year Study
- 17 Downloads
The objective of this study is to estimate the prevalence, management and follow-up of gestational trophoblastic disease (GTD) in a tertiary care center, Royal Hospital, in Oman over the last 11 years from January 2007 till December 2017. This study also looked into the reproductive outcome after trophoblastic disease treatment.
This retrospective, descriptive study was carried out at Royal Hospital from Jan. 2007 to Dec. 2017. All cases with a histopathological report of hydatidiform molar disease were included. Demographic characteristics, clinical presentation physical signs, treatment and follow-up including reproductive outcome and recurrence rate were included.
Two hundred and thirty-six women with GTD were included in the study. Mean maternal age was 35 years, mean gravidity 5 and parity 3. Prevalence of complete mole was 83 cases (35.1%), partial mole 144 cases (61%), choriocarcinoma (0.42%), placental site (0.42%) and invasive mole (1.27%). Thyrotoxicosis, preeclampsia and anemia were 3.8%, 7.2% and 0.8%, respectively. Mean gestational age was 10.57 ± 3.2 weeks at presentation. Persistent disease was observed in 12.3%. About 5% received chemotherapy. Metastasis was reported in 4.7% of cases, 81.8% to the lung. About 38% conceived later.
This study highlights the importance of proper assessment and follow-up of histopathology diagnosis. GTD usually has a good prognosis and reproductive outcome if properly followed up and treated.
KeywordsGestational trophoblastic disease Molar pregnancy Partial molar pregnancy Metastases Prevalence
Compliance with Ethical Standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 2.Gestational trophoblastic disease, New Zealand gynaecologic cancer group guidelines, March 2018. https://www.health.govt.nz/system/files/documents/publications/gtd-guidelines-2018.pdf.
- 5.Ahmed IAM. Gestational trophoblastic disease in Al-Thawra Hospital, Sana’a-Yemen. Yemeni J Med Sci. 2013;7.Google Scholar
- 6.Al Alaf SK, Ibrahim D. Prevalence and clinical observations of gestational trophoblastic diseases in maternity teaching hospital in Erbil city. WSEAS Trans. Biol. Biomed. 2010;7(3):190–9.Google Scholar
- 7.Javey H, Sajadi H. Hydatidiform mole in southern Iran: a statistical survey of 113 cases. Int J Gynaecol Obstet. 1978;15(5):390–5. https://doi.org/10.1002/j.1879-3479.1977.tb00716.x.CrossRefPubMedGoogle Scholar
- 10.Seckl MJ, Sebire NJ, Fisher RA, Golfier F, Massuger L, Sessa C, ESMO Guidelines Working Group Annals of Oncology. Gestational trophoblastic disease: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(suppl_6):vi39–50. https://doi.org/10.1093/annonc/mdt345.CrossRefPubMedGoogle Scholar
- 11.Al Riyami N, Al Riyami M, Al Hajiri T, Al Saidi S, Salman B, Kalbani M. Gestational trophoblastic disease at Sultan Qaboos University Hospital: prevalence, risk factors, histological features, sonographic findings, and outcomes. Oman Med J. 2019;34(3):200–4. https://doi.org/10.5001/omj.2019.39).CrossRefPubMedPubMedCentralGoogle Scholar